298205-14-8

Basic information

• Product Name: 2,5-dimethyl-1-[[4-[2-(2-methyl-4-thiazolyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]-1H-pyrrole
• Synonyms: 2,5-dimethyl-1-[[4-[2-(2-methyl-4-thiazolyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]-1H-pyrrole
• CAS NO: 298205-14-8
• Molecular Weight: 466.508
• Mol File: 298205-14-8.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2,5-dimethyl-1-[[4-[2-(2-methyl-4-thiazolyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]-1H-pyrrole(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5-dimethyl-1-[[4-[2-(2-methyl-4-thiazolyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]-1H-pyrrole(298205-14-8)
• EPA Substance Registry System: 2,5-dimethyl-1-[[4-[2-(2-methyl-4-thiazolyl)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]-1H-pyrrole(298205-14-8)

Safety Data

• Hazardous Substances Data: 298205-14-8(Hazardous Substances Data)

Upstream product

• 194467-71-5 4-[(2,5-dimethyl-1H-pyrrol-1-yl)sulfonyl]benzenamine 
• 21917-76-0 2-methylthiazol-4-carbonitrile 
• 194467-70-4 2,5-dimethyl-1-[(4-nitrophenyl)sulfonyl]-1H-pyrrole 
• 110-13-4 2,5-hexanedione 
• 6325-93-5 p-nitrobenzenesulfonamide 
• 298205-13-7 1-[[-[4,5-dihydro-4-hydroxy-2-(2-methyl-4-thiazol)-4-(trifluoromethyl)-1H-imidazol-1-yl]phenyl]sulfonyl]-2,5-dimethyl-1H-pyrrole 

Relevant articles and documents

Selective cyclooxygenase-2 inhibitors: Heteroaryl modified 1,2-diarylimidazoles are potent, orally active antiinflammatory agents

A series of heteroaryl modified 1,2-diarylimidazoles has been synthesized and found to be potent and highly selective (1000-9000-fold) inhibitors of the human COX-2.3-Pyridyl derived COX-2 selective inhibitor (25) exhibited excellent activity in acute (carrageenan induced paw edema, ED50 = 5.4 mg/kg) and chronic (adjuvant induced arthritis, ED50 = 0.25 mg/kg) models of inflammation. The relatively long half-life of 25 in rat and dog prompted investigation of the pyridyl and other heteroaromatic systems containing potential metabolic functionalities. A number of substituted pyridyl and thiazole containing compounds (e.g., 44, 46, 54, 76, and 78) demonstrated excellent oral activity in every efficacy model evaluated. Several orally active diarylimidazoles exhibited desirable pharmacokinetics profiles and showed no GI toxicity in the rat up to 100 mg/kg in both acute and chronic models. The paper describes facile and practical syntheses of the targeted diarylimidazoles. The structure-activity relationships and antiinflammatory properties of a series of diarylimidazoles are discussed.